Ng IO - Search Results

1

P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation.

Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng IO. Ching YP, et al. Among authors: ng io. Cancer Res. 2007 Apr 15;67(8):3601-8. doi: 10.1158/0008-5472.CAN-06-3994. Cancer Res. 2007. PMID: 17440071

2

High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation.

Chan KL, Lee JM, Guan XY, Fan ST, Ng IO. Chan KL, et al. Among authors: ng io. Cancer. 2002 Jun 15;94(12):3179-85. doi: 10.1002/cncr.10612. Cancer. 2002. PMID: 12115350 Free article.

3

Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.

Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, Ng IO. Ching YP, et al. Among authors: ng io, ng dc. J Biol Chem. 2003 Mar 21;278(12):10824-30. doi: 10.1074/jbc.M208310200. Epub 2003 Jan 16. J Biol Chem. 2003. PMID: 12531887 Free article.

4

Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma.

Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST. Ren Y, et al. Among authors: ng io. Int J Cancer. 2003 Oct 20;107(1):22-9. doi: 10.1002/ijc.11287. Int J Cancer. 2003. PMID: 12925952

5

Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.

Wong CM, Lee JM, Ching YP, Jin DY, Ng IO. Wong CM, et al. Among authors: ng io. Cancer Res. 2003 Nov 15;63(22):7646-51. Cancer Res. 2003. PMID: 14633684

6

Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma.

Lee TK, Man K, Poon RT, Lo CM, Ng IO, Fan ST. Lee TK, et al. Among authors: ng io. Oncol Rep. 2004 Jul;12(1):25-31. Oncol Rep. 2004. PMID: 15201954

7

Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.

Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, Ng IO. Chan CF, et al. Among authors: ng io. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4140-9. doi: 10.1158/1078-0432.CCR-03-0574. Clin Cancer Res. 2004. PMID: 15217951

8

HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing.

Yau TO, Chan CY, Chan KL, Lee MF, Wong CM, Fan ST, Ng IO. Yau TO, et al. Among authors: ng io. Oncogene. 2005 Feb 24;24(9):1607-14. doi: 10.1038/sj.onc.1208340. Oncogene. 2005. PMID: 15580286

9

Association of MAD2 expression with mitotic checkpoint competence in hepatoma cells.

Sze KM, Ching YP, Jin DY, Ng IO. Sze KM, et al. Among authors: ng io. J Biomed Sci. 2004 Nov-Dec;11(6):920-7. doi: 10.1007/BF02254377. J Biomed Sci. 2004. PMID: 15591789

10

High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma.

Chan KL, Guan XY, Ng IO. Chan KL, et al. Among authors: ng io. Hum Pathol. 2004 Nov;35(11):1324-31. doi: 10.1016/j.humpath.2004.06.012. Hum Pathol. 2004. PMID: 15668888

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

440 results

Search Page

Filters